Compugen (NASDAQ:CGEN) Stock Price Passes Above Two Hundred Day Moving Average – Time to Sell?

Compugen Ltd. (NASDAQ:CGEN) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.17 and traded as high as $2.44. Compugen shares last traded at $2.41, with a volume of 370,673 shares changing hands.

Analyst Upgrades and Downgrades

CGEN has been the subject of several research reports. Truist Financial upgraded Compugen to a “strong-buy” rating in a research report on Wednesday, March 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Compugen in a report on Monday, April 20th. Wall Street Zen cut shares of Compugen from a “buy” rating to a “hold” rating in a research note on Saturday, May 23rd. Lake Street Capital began coverage on shares of Compugen in a report on Tuesday, April 7th. They set a “buy” rating and a $6.00 target price for the company. Finally, Leerink Partners reduced their target price on shares of Compugen from $13.00 to $5.00 and set an “outperform” rating for the company in a research report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Compugen currently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Compugen Price Performance

The stock has a market capitalization of $227.87 million, a price-to-earnings ratio of 6.51 and a beta of 2.76. The business has a fifty day moving average of $2.41 and a 200 day moving average of $2.17.

Compugen (NASDAQ:CGEN) last posted its earnings results on Monday, May 18th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). Compugen had a return on equity of 47.72% and a net margin of 47.97%.The business had revenue of $2.18 million for the quarter, compared to analyst estimates of $1.57 million. On average, equities research analysts expect that Compugen Ltd. will post -0.28 EPS for the current year.

Institutional Trading of Compugen

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC boosted its stake in Compugen by 1,077.0% during the second quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after buying an additional 359,785 shares during the period. Renaissance Technologies LLC raised its stake in shares of Compugen by 12.1% in the 1st quarter. Renaissance Technologies LLC now owns 1,632,988 shares of the biotechnology company’s stock valued at $3,478,000 after acquiring an additional 176,088 shares during the period. XTX Topco Ltd purchased a new stake in shares of Compugen in the 4th quarter valued at approximately $104,000. Marshall Wace LLP lifted its holdings in shares of Compugen by 135.7% in the 4th quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock worth $163,000 after acquiring an additional 61,202 shares during the last quarter. Finally, WINTON GROUP Ltd purchased a new position in shares of Compugen during the 4th quarter worth approximately $84,000. 12.22% of the stock is currently owned by hedge funds and other institutional investors.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.